Oversight, Office of Research Integrity, 1101 Wooton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research Integrity.

[FR Doc. 2010–31108 Filed 12–10–10; 8:45 am]
BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Priority Setting for the Children's Health Insurance Program Reauthorization Act (CHIPRA) Pediatric Quality Measures Program—Notice of Correction

On pages 75469 and 75470, Volume 75, Number 232, Federal Register notice publication dated December 3, 2010, under DATES section, the correct date is: January 14, 2011. Also, on pages 75470 and 75471, under section SUPPLEMENTARY INFORMATION all Web links that include the word: "ahrg" should be changed to: "AHRQ".

Carolyn M. Clancy,
Director, AHRQ.

[FR Doc. C1–2010–31110 Filed 12–10–10; 8:45 am]
BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket Number NIOSH–219]

Implementation of Section 2695 (42 U.S.C. 300ff–131) of Public Law 111–87: Infectious Diseases and Circumstances Relevant to Notification Requirements

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services.

ACTION: General Notice and Request for Comments.

SUMMARY: The Ryan White HIV/AIDS Treatment Extension Act of 2009 (Pub. L. 111–87) amends the Public Health Service Act (PHS Act, 42 U.S.C. 201–300ij), including the addition of a Part G to Title XXVI, which addresses notification procedures and requirements for medical facilities, State public health officers and their designated officers regarding exposure of EREs to potentially life-threatening infectious diseases. (See Title XXVI, Part G of the PHS Act, codified as amended at 42 U.S.C. 300ff–131 to 300ff–140.) For purposes of these notification requirements, Section 2695 (42 U.S.C. 300ff–131) requires the Secretary of Health and Human Services (Secretary) to develop and disseminate:

1. A list of potentially life-threatening infectious diseases,